

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
20 January 2005 (20.01.2005)

PCT

(10) International Publication Number
WO 2005/005416 A1

(51) International Patent Classification: C07D 403/06,
207/36, A61K 31/4439, 31/4025, A61P 3/10, 25/28

(21) International Application Number:
PCT/SE2004/001115

(22) International Filing Date: 8 July 2004 (08.07.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0316237.7 11 July 2003 (11.07.2003) GB

(71) Applicant (for all designated States except US): AS-
TRAZENECA AB [SE/SU]; S-151 85 Södertälje (SE).

(72) Inventor; and

(75) Inventor/Applicant (for US only): HOLM, Patrik
[US/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal
(SE).

(74) Agent: ASTRAZENECA; Global Intellectual Property,
S-151 85 Södertälje (SE).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AF, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, GN, GT, GU, HK, HN, HU, ID, IL, IN, JP,
KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SI, SK,
TR), OAPI (BF, BJ, CI, CG, CO, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:


— as to applicant's entitlement to apply for and be granted
a patent (Rule 4.17(ii)) for the following designations: AF,
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ,
CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE,
EG, ES, FI, GE, GD, GH, GM, GN, GU, HK, HN, HU, ID, IL, IN, IS,
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM,
PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM,
ZW. ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA,
SD, SL, SZ, TZ, UG, ZM, ZW). Eurasian patent (AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM). European patent (AT, BE,
BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR). OAPI patent
(BF, BJ, CI, CG, CO, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG).

Published:

— with international search report
— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guide-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: PYRROLE-2, 5-DITHIONE DERIVATIVES AS LIVER X RECEPTOR MODULATORS



I

(57) Abstract: The present invention relates to certain novel com-
pounds of the Formula I to processes for preparing such compounds,
to their utility in modulation of nuclear hormone receptors Liver X
Receptor (LXR) α (NR1H3) and/or β (NR1H2) and in treating clinical
conditions including cardiovascular diseases such as atherosclerosis;
inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipi-
demias) whether or not associated with insulin resistance, type 2 dia-
betes and other manifestations of the metabolic syndrome, to methods
for their therapeutic use and to pharmaceutical compositions contain-
ing them.

WO 2005/005416 A1

BEST AVAILABLE COPY